Literature DB >> 8938830

Clozapine plasma level monitoring: current status.

T B Cooper1.   

Abstract

Plasma level monitoring of clozapine and metabolites may prove beneficial in treating patients who show unusual drug metabolic activity. A threshold plasma level for patients who will respond to this medication is suggested. The interaction of gender, age, smoking, other medication and side effects with plasma clozapine and metabolites are discussed. Plasma level monitoring of clozapine and/or metabolites is recommended in patients who do not respond at usual therapeutic dose, who show untoward side effects at low dose or who are treated with other medications. Finally monitoring of patients who require more than 600 mg/day should be implemented because there is evidence that the incidence of seizures increases significantly above this dosage level. There is some evidence that high plasma clozapine levels are associated with seizures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938830     DOI: 10.1007/bf02326373

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  70 in total

1.  Influence of patient-related variables on clozapine plasma levels.

Authors:  C Haring; W W Fleischhacker; P Schett; C Humpel; C Barnas; A Saria
Journal:  Am J Psychiatry       Date:  1990-11       Impact factor: 18.112

2.  Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites.

Authors:  F Centorrino; R J Baldessarini; J G Flood; J C Kando; F R Frankenburg
Journal:  Am J Psychiatry       Date:  1995-04       Impact factor: 18.112

3.  Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients.

Authors:  M G Choc; F Hsuan; G Honigfeld; W T Robinson; L Ereshefsky; M L Crismon; S R Saklad; J Hirschowitz; R Wagner
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

4.  Determination of clozapine and its major metabolites in human serum and rat plasma by liquid chromatography using solid-phase extraction and ultraviolet detection.

Authors:  E O Fadiran; J Leslie; M Fossler; D Young
Journal:  J Pharm Biomed Anal       Date:  1995-02       Impact factor: 3.935

5.  Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

Authors:  M H Kronig; R A Munne; S Szymanski; A Z Safferman; S Pollack; T Cooper; J M Kane; J A Lieberman
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

6.  Clozapine-related seizures.

Authors:  O Devinsky; G Honigfeld; J Patin
Journal:  Neurology       Date:  1991-03       Impact factor: 9.910

7.  Thermal degradation of clozapine-N-oxide to clozapine during gas chromatographic analysis.

Authors:  J S Markowitz; K S Patrick
Journal:  J Chromatogr B Biomed Appl       Date:  1995-06-09

8.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

9.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

Authors:  A L Nordström; L Farde; S Nyberg; P Karlsson; C Halldin; G Sedvall
Journal:  Am J Psychiatry       Date:  1995-10       Impact factor: 18.112

10.  Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection.

Authors:  P T McCarthy; S Hughes; C Paton
Journal:  Biomed Chromatogr       Date:  1995 Jan-Feb       Impact factor: 1.902

View more
  7 in total

1.  Comparability of whole-blood and plasma clozapine and norclozapine concentrations.

Authors:  R J Flanagan; B Yusufi; T R E Barnes
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 2.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

Review 5.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

6.  Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia.

Authors:  Joomi Lee; Min-Gul Kim; Hyeon-Cheol Jeong; Kwang-Hee Shin
Journal:  Transl Clin Pharmacol       Date:  2021-03-10

Review 7.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.